Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 94.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,548 shares of the company’s stock after selling 592,930 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Neumora Therapeutics were worth $346,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Capital International Investors boosted its stake in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock worth $39,224,000 after purchasing an additional 3,233,179 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock worth $48,466,000 after acquiring an additional 195,142 shares during the period. Rock Springs Capital Management LP lifted its holdings in shares of Neumora Therapeutics by 15.3% during the 4th quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company’s stock worth $10,124,000 after acquiring an additional 127,005 shares during the period. Swiss National Bank purchased a new position in Neumora Therapeutics in the fourth quarter valued at approximately $1,168,000. Finally, Norges Bank purchased a new position in Neumora Therapeutics in the fourth quarter valued at approximately $1,166,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Down 9.5%

Shares of Neumora Therapeutics stock opened at $0.62 on Thursday. The company’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $4.50. Neumora Therapeutics, Inc. has a 52 week low of $0.61 and a 52 week high of $17.19. The stock has a market cap of $99.49 million, a PE ratio of -0.33 and a beta of 2.96.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). On average, equities analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on NMRA shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Bank of America reaffirmed an “underperform” rating and issued a $1.00 price objective (down previously from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Stifel Nicolaus cut Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the company from $6.00 to $2.00 in a research note on Friday, March 7th. Finally, HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Neumora Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $9.29.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.